Tepotinib (Mechanism of Action)
Tepotinib is a targeted therapy drug approved for the treatment of metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations. Here are key details about tepotinib:
Mechanism of Action
MET Inhibitor: Tepotinib is a selective inhibitor of the MET receptor tyrosine kinase. Mutations or alterations in the MET gene can lead to uncontrolled cell growth and cancer. By inhibiting MET, tepotinib helps prevent cancer cell proliferation and survival.